FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200243721> ?p ?o ?g. }

• W4200243721 abstract "ABSTRACT Background Multigene expression assays for molecular subtypes and biomarkers can aid clinical management of early invasive breast cancer (IBC). Based on RNA-sequencing we aimed to develop robust single-sample predictor (SSP) models for conventional clinical markers as well as molecular intrinsic subtype and risk of recurrence (ROR) that provide clinically relevant prognostic stratification. Methods A uniformly accrued breast cancer cohort of 7743 patients with RNA-sequencing data from fresh tissue was divided into a training set (n=5250) and a reserved test set (n=2412). We trained SSPs for PAM50 molecular subtypes and ROR assigned by nearest-centroid (NC) methods and SSPs for conventional clinical markers from histopathology data. Additionally, SSP classifications were compared with Prosigna in two external cohorts (ABiM, n=100 and OSLO2-EMIT0, n=103). Prognostic value was assessed using distant recurrence-free interval (DRFi). Results In the test set, agreement between SSP and NC classifications for PAM50 (five subtypes) and Subtype (four subtypes) was high (85%, Kappa=0.78) and very high (90%, Kappa=0.84) respectively. Accuracy for ROR risk category was high (84%, Kappa=0.75, weighted Kappa=0.90). The prognostic value for SSP and NC classification was assessed as equivalent and added clinically relevant prognostic information. Agreement for SSP and histopathology was very high or high for receptor status, while moderate and poor for Ki67 status and Nottingham histological grade, respectively. SSP concordance with Prosigna was high for subtype (OSLO 83% and ABiM 80%, Kappa=0.73 and 0.72, respectively) and moderate and high for ROR risk category (68% and 84%, Kappa=0.50 and 0.70, weighted Kappa=0.70 and 0.78). In pooled analysis, concordance between SSP and Prosigna for emulated treatment recommendation dichotomized for chemotherapy (yes vs. no) was high (85%, Kappa=0.66). In postmenopausal ER+/HER2-/N0 patients SSP application suggested changed treatment recommendations for up to 17% of patients, with nearly balanced escalation and de-escalation of chemotherapy. Conclusions Robust SSP models, mimicking histopathological variables, PAM50, and ROR classifications can be derived from RNA-sequencing that closely matches clinical tests. Agreement and DRFi analyses suggest that NC and SSP models are interchangeable on a group-level and nearly so on a patient level. Retrospective evaluation in ER+/HER2-/N0 IBC suggested that molecular testing could lead to a changed therapy recommendation for almost one-fifth of patients." @default.
• W4200243721 created "2021-12-31" @default.
• W4200243721 creator A5001565523 @default.
• W4200243721 creator A5008691716 @default.
• W4200243721 creator A5010340306 @default.
• W4200243721 creator A5012236395 @default.
• W4200243721 creator A5016805282 @default.
• W4200243721 creator A5022400466 @default.
• W4200243721 creator A5022671016 @default.
• W4200243721 creator A5025171844 @default.
• W4200243721 creator A5033640021 @default.
• W4200243721 creator A5037959387 @default.
• W4200243721 creator A5040610749 @default.
• W4200243721 creator A5043846022 @default.
• W4200243721 creator A5045322799 @default.
• W4200243721 creator A5048408312 @default.
• W4200243721 creator A5052676245 @default.
• W4200243721 creator A5055602080 @default.
• W4200243721 creator A5056172056 @default.
• W4200243721 creator A5057328031 @default.
• W4200243721 creator A5061921179 @default.
• W4200243721 creator A5064241846 @default.
• W4200243721 creator A5065433718 @default.
• W4200243721 creator A5068760861 @default.
• W4200243721 creator A5070951926 @default.
• W4200243721 creator A5074367632 @default.
• W4200243721 creator A5082508483 @default.
• W4200243721 date "2021-12-05" @default.
• W4200243721 modified "2023-09-30" @default.
• W4200243721 title "RNA Sequencing-Based Single Sample Predictors of Molecular Subtype and Risk of Recurrence for Clinical Assessment of Early-Stage Breast Cancer" @default.
• W4200243721 cites W1976022788 @default.
• W4200243721 cites W1976173969 @default.
• W4200243721 cites W2035793132 @default.
• W4200243721 cites W2037497419 @default.
• W4200243721 cites W2074465378 @default.
• W4200243721 cites W2097216790 @default.
• W4200243721 cites W2102278945 @default.
• W4200243721 cites W2104005232 @default.
• W4200243721 cites W2106833357 @default.
• W4200243721 cites W2115528316 @default.
• W4200243721 cites W2117775530 @default.
• W4200243721 cites W2118413367 @default.
• W4200243721 cites W2118632896 @default.
• W4200243721 cites W2119589567 @default.
• W4200243721 cites W2124640147 @default.
• W4200243721 cites W2131271579 @default.
• W4200243721 cites W2132619562 @default.
• W4200243721 cites W2133987488 @default.
• W4200243721 cites W2150524410 @default.
• W4200243721 cites W2157168213 @default.
• W4200243721 cites W2157840751 @default.
• W4200243721 cites W2160216944 @default.
• W4200243721 cites W2170551349 @default.
• W4200243721 cites W2344022496 @default.
• W4200243721 cites W2403389346 @default.
• W4200243721 cites W2517421365 @default.
• W4200243721 cites W2559344092 @default.
• W4200243721 cites W2601262142 @default.
• W4200243721 cites W2762467945 @default.
• W4200243721 cites W2770650192 @default.
• W4200243721 cites W2771177310 @default.
• W4200243721 cites W2784497242 @default.
• W4200243721 cites W2787188812 @default.
• W4200243721 cites W2792135005 @default.
• W4200243721 cites W2805734855 @default.
• W4200243721 cites W2898598946 @default.
• W4200243721 cites W2912573440 @default.
• W4200243721 cites W2947463548 @default.
• W4200243721 cites W2947890877 @default.
• W4200243721 cites W2949017090 @default.
• W4200243721 cites W2964849163 @default.
• W4200243721 cites W2969520627 @default.
• W4200243721 cites W2976898289 @default.
• W4200243721 cites W2992466184 @default.
• W4200243721 cites W3005471759 @default.
• W4200243721 cites W3087034042 @default.
• W4200243721 cites W3096696431 @default.
• W4200243721 cites W3134192669 @default.
• W4200243721 cites W3155215767 @default.
• W4200243721 cites W3165771626 @default.
• W4200243721 cites W4200339421 @default.
• W4200243721 cites W4213418594 @default.
• W4200243721 doi "https://doi.org/10.1101/2021.12.03.21267116" @default.
• W4200243721 hasPublicationYear "2021" @default.
• W4200243721 type Work @default.
• W4200243721 citedByCount "1" @default.
• W4200243721 countsByYear W42002437212023 @default.
• W4200243721 crossrefType "posted-content" @default.
• W4200243721 hasAuthorship W4200243721A5001565523 @default.
• W4200243721 hasAuthorship W4200243721A5008691716 @default.
• W4200243721 hasAuthorship W4200243721A5010340306 @default.
• W4200243721 hasAuthorship W4200243721A5012236395 @default.
• W4200243721 hasAuthorship W4200243721A5016805282 @default.
• W4200243721 hasAuthorship W4200243721A5022400466 @default.
• W4200243721 hasAuthorship W4200243721A5022671016 @default.
• W4200243721 hasAuthorship W4200243721A5025171844 @default.
• W4200243721 hasAuthorship W4200243721A5033640021 @default.
• W4200243721 hasAuthorship W4200243721A5037959387 @default.
• W4200243721 hasAuthorship W4200243721A5040610749 @default.
• W4200243721 hasAuthorship W4200243721A5043846022 @default.

• next